Comparative analysis of IC50 among all reported AMPs against HCC cells revealed that myristoyl-CM4 demonstrated superior anticancer potency to most of the reported AMPs, with melittin and its derivatives being the only compound that surpassed it in efficacy. This evidence concerns the gene ADSL and hepatocellular carcinoma.